Proteomics technologies are becoming indispensable in pre-clinical pharmaceutical discovery, driven by advancements in mass spectrometry and analytical workflows. This article explores how industrial-scale proteomics enables comprehensive proteome profiling, leading to breakthroughs in targeting complex diseases.
Comments